190 related articles for article (PubMed ID: 29497279)
1. Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.
Kim YK; Shin KH; Alderman J; Yu KS; Jang IJ; Lee S
Drug Des Devel Ther; 2018; 12():331-337. PubMed ID: 29497279
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration.
Milton KA; Scott NR; Allen MJ; Abel S; Jenkins VC; James GC; Rance DJ; Eve MD
J Clin Pharmacol; 2002 May; 42(5):528-39. PubMed ID: 12017347
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and safety of single escalating oral doses of eletriptan.
Shah AK; Harris SC; Greenhalgh C; Morganroth J
J Clin Pharmacol; 2002 May; 42(5):520-7. PubMed ID: 12017346
[TBL] [Abstract][Full Text] [Related]
4. Eletriptan: a review of its use in the acute treatment of migraine.
McCormack PL; Keating GM
Drugs; 2006; 66(8):1129-49. PubMed ID: 16789799
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Wade A; Pawsey S; Whale H; Boyce M; Warrington S
Clin Drug Investig; 2009; 29(5):325-37. PubMed ID: 19366274
[TBL] [Abstract][Full Text] [Related]
6. One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan.
Patel H; Patel P; Modi N; Shah S; Ghoghari A; Variya B; Laddha R; Baradia D; Dobaria N; Mehta P; Srinivas NR
Eur J Pharm Sci; 2017 Aug; 106():87-93. PubMed ID: 28549679
[TBL] [Abstract][Full Text] [Related]
7. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
[TBL] [Abstract][Full Text] [Related]
8. Eletriptan.
Gawel MJ; Grujich NN
Expert Opin Investig Drugs; 2001 Oct; 10(10):1869-74. PubMed ID: 11772292
[TBL] [Abstract][Full Text] [Related]
9. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study.
Almas M; Tepper SJ; Landy S; Schweizer E; Ramos E
Cephalalgia; 2014 Feb; 34(2):126-35. PubMed ID: 23946318
[TBL] [Abstract][Full Text] [Related]
10. WITHDRAWN: Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2007 Jul; 2001(1):CD003224. PubMed ID: 17636718
[TBL] [Abstract][Full Text] [Related]
11. Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2001; (3):CD003224. PubMed ID: 11687056
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study.
Choi Y; Lee S; Cho SM; Kang WH; Nam KY; Jang IJ; Yu KS
Drug Des Devel Ther; 2016; 10():3021-3028. PubMed ID: 27703330
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of eletriptan in the treatment of acute migraine.
Takiya L; Piccininni LC; Kamath V
Pharmacotherapy; 2006 Jan; 26(1):115-28. PubMed ID: 16506353
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks.
Stark R; Dahlöf C; Haughie S; Hettiarachchi J;
Cephalalgia; 2002 Feb; 22(1):23-32. PubMed ID: 11993610
[TBL] [Abstract][Full Text] [Related]
16. Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
Marcus DA; Bernstein CD; Sullivan EA; Rudy TE
Headache; 2010 Apr; 50(4):551-62. PubMed ID: 20236337
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
Berges A; Walls C; Lener SE; McDonald SA
Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers.
Shah AK; Laboy-Goral L; Scott N; Morse T; Apseloff G
J Clin Pharmacol; 2001 Dec; 41(12):1339-44. PubMed ID: 11762561
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on eletriptan in migraine.
McCormack PL; Keating GM
CNS Drugs; 2006; 20(11):961-4. PubMed ID: 17044732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
